One of the most promising Chinese vaccine candidates has triggered the production of antibodies in human tests and has so far been free of side effects. This is what researchers report.
The vaccine “BBIBP-CorV” was developed by the Beijing Institute for Biological Products. It will only be recognized if it has successfully passed the so-called Phase III studies.
According to the World Health Organization, “BBIBP-CorV” is one of at least ten vaccines that have started “Phase III”.